Hopeful law firms in search of plaintiffs for kickback suits against Sanofi

Sanofi ($SNY) made its fair share of bad headlines in the latter half of 2014, and law firms are hoping that means one thing: plaintiffs for shareholder lawsuits against the French drugmaker. Potential claims focus on an alleged illegal kickback strategy for the company's diabetes franchise, designed to boost sales. More

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.